Patents by Inventor Leonardo Jose Borras
Leonardo Jose Borras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210214461Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.Type: ApplicationFiled: August 19, 2020Publication date: July 15, 2021Inventors: David Urech, Leonardo Jose Borras
-
Publication number: 20200172608Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: January 31, 2020Publication date: June 4, 2020Inventors: Leonardo Jose Borras, David Urech, Tea Gunde
-
Patent number: 10570198Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: February 18, 2016Date of Patent: February 25, 2020Assignee: NOVARTIS AGInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20200048336Abstract: The invention provides antibodies that bind to multiple antigens, said antibodies having at least two antibody light chain variable domains and two antibody heavy chain variable domains, wherein each light chain variable domain is linked to a heavy chain variable domain to form a VH/VL construct, and wherein at least one of the VH domains comprises a particular amino acid at AHo position 12, 103 and/or 144, and at least one of the VL domains comprises a particular amino acid at AHo position 47 and/or 50. Nucleic acid molecules, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them, and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: February 27, 2019Publication date: February 13, 2020Inventors: Astrid C. Riegler, Leonardo Jose Borras, Roberto Sommavilla
-
Patent number: 10087244Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: GrantFiled: December 10, 2015Date of Patent: October 2, 2018Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Patent number: 9803027Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.Type: GrantFiled: June 19, 2014Date of Patent: October 31, 2017Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: David Urech, Leonardo Jose Borras
-
Patent number: 9598487Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: August 28, 2013Date of Patent: March 21, 2017Assignee: ESBATech, an Alcon Biomedical Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Patent number: 9593161Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: GrantFiled: February 12, 2014Date of Patent: March 14, 2017Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20160176959Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: February 18, 2016Publication date: June 23, 2016Inventors: Leonardo Jose Borras, David Urech
-
Publication number: 20160096903Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: ApplicationFiled: December 10, 2015Publication date: April 7, 2016Inventors: Leonardo Jose Borras, David Urech
-
Publication number: 20150080555Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.Type: ApplicationFiled: June 19, 2014Publication date: March 19, 2015Inventors: David Urech, Leonardo Jose Borras
-
Publication number: 20140221624Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.Type: ApplicationFiled: February 12, 2014Publication date: August 7, 2014Applicant: ESBATech - a Novartis Company LLCInventors: Leonardo Jose Borras, David Urech
-
Patent number: 8796425Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.Type: GrantFiled: December 21, 2010Date of Patent: August 5, 2014Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: David Urech, Leonardo Jose Borras
-
Publication number: 20130344086Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: ESBATech, An Alcon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Patent number: 8545849Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: October 21, 2011Date of Patent: October 1, 2013Assignee: ESBATech, an Aclon Biomedical Research Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20120100153Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT, LLCInventors: Leonardo Jose Borras, David Urech
-
Publication number: 20110152505Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.Type: ApplicationFiled: December 21, 2010Publication date: June 23, 2011Applicant: ESBATECH AN ALCON BIOMEDICAL RESEARCH UNIT LLCInventors: David Urech, Tea Gunde, Leonardo Jose Borras